EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)

Phillip H Kuo, Michael J Morris iD, Jacob Hesterman, A Tuba Kendi iD, Kambiz Rahbar iD, Xiao X Wei iD, Bruno Fang, Nabil Adra, Rohan Garje, Jeff M Michalski, Kim Chi, Johann de Bono iD und 11 weitere

Radiology · 01.08.2024 · 312 (2)

DOI: 10.1148/radiol.233460 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Radiology, erschienen am 01.08.2024. Verfasst von Phillip H Kuo und 22 weiteren Autor:innen. Beteiligte Einrichtung: From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); …. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Lutetium. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Visual 68 Ga-PSMA-11 PET/CT eligibility criteria helped identify participants with metastatic castration-resistant prostate cancer who benefitted from 177 Lu-PSMA-617 therapy in the VISION trial, with higher 68 Ga-PSMA-11 uptake associated with improved outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesProstatic Neoplasms, Castration-ResistantPositron Emission Tomography Computed TomographyLutetiumGallium IsotopesHeterocyclic Compounds, 1-RingDipeptidesRadiopharmaceuticalsHumansMaleAgedMiddle AgedTreatment OutcomeRadioisotopesEdetic AcidProstate-Specific Antigen

Substanzen

Gallium RadioisotopesLutetiumGallium IsotopesHeterocyclic Compounds, 1-Ringgallium 68 PSMA-11DipeptidesPluvictoRadiopharmaceuticalsRadioisotopesEdetic Acid

Autor:innen und Institutionen

  • From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Med…

ORCID-Profile: Michael J Morris, A Tuba Kendi, Kambiz Rahbar, Xiao X Wei, Johann de Bono, Bernd Krause, Oliver Sartor, Marcia Brackman, Andrew J Armstrong, Ken Herrmann

Förderung

  • NCI NIH HHS

Zitieren

APA

Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., Chi, K., de Bono, J., Fizazi, K., Krause, B., Sartor, O., Tagawa, S. T., Ghebremariam, S., Brackman, M., Wong, C. C., …, & Herrmann, K. (2024). Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial). Radiology, 312(2). https://doi.org/10.1148/radiol.233460

Vancouver

Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2). doi:10.1148/radiol.233460

BibTeX
@article{Kuo2024,
  author = {Kuo, Phillip H and Morris, Michael J and Hesterman, Jacob and Kendi, A Tuba and Rahbar, Kambiz and Wei, Xiao X and Fang, Bruno and Adra, Nabil and Garje, Rohan and Michalski, Jeff M and Chi, Kim and de Bono, Johann and Fizazi, Karim and Krause, Bernd and Sartor, Oliver and Tagawa, Scott T and Ghebremariam, Samson and Brackman, Marcia and Wong, Connie C and Catafau, Ana M and Benson, Taylor and Armstrong, Andrew J and Herrmann, Ken},
  title = {Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)},
  journal = {Radiology},
  year = {2024},
  volume = {312},
  number = {2},
  doi = {10.1148/radiol.233460}
}
Kostenlos starten →